Cargando…

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC‐486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John C., Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221082/ https://www.ncbi.nlm.nih.gov/pubmed/30016552 http://dx.doi.org/10.1002/ajh.25216

Ejemplares similares

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
por: Babiker, Hani M., et al.
Publicado: (2020)

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
por: de Lima, Marcos, et al.
Publicado: (2018)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
por: Heumann, Thatcher R., et al.
Publicado: (2022)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
por: Chen, Yong, et al.
Publicado: (2010)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
por: Döhner, Hartmut, et al.
Publicado: (2018)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
por: Amaya, Maria, et al.
Publicado: (2023)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
por: Kara, Asude, et al.
Publicado: (2017)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Azacitidine-Induced Pneumonitis in a Patient With Acute Myeloid Leukemia and Hyperleukocytosis
por: Litvin, Rafaella, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia
por: Ninawe, Anupama, et al.
Publicado: (2021)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient
por: Powers, Harry Ross, et al.
Publicado: (2014)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
por: Roboz, Gail J., et al.
Publicado: (2021)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

MiR‐486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro
por: Jiang, Jingwei, et al.
Publicado: (2018)

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
por: Cluzeau, Thomas, et al.
Publicado: (2014)

Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia
por: Sadashiv, Santhosh K, et al.
Publicado: (2014)

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia
por: Min, Chengyin, et al.
Publicado: (2017)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jll888p1s14qkkgokmc5p6ft1p